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ABSTRACT
Recent theory concerning the mechanisms by which RNA-tumor viruses are trans-
mitted in animals and their genetic information expressed during embryogenesis and
adulthood is reviewed. An implication of such theory has been that adult animals are
immunotolerant to the group-specific (gs) RNA-tumor-virus antigens, though there is
evidence that refutes this implication.
On the basis that most mammals are not immunotolerant to the interspecies gs RNA-
tumor-virus antigen, human sera from patients with various malignant diseases, from
normal family members of these patients, and from other normal individuals were ex-
amined for antibodies to interspecies gs antigen. Using complement-fixation inhibition
tests, a significant proportion of patients with rhabdomyosarcoma, osteogenic sarcoma,
acute lymphocytic leukemia, or breast cancer gave positive reactions. A second test,
inhibition of the paired radioiodine-labeled antibody technique, confirmed the results with
sera from patients with rhabdomyosarcoma. The results are interpreted as serologic
evidence of a human RNA-tumor virus. Other types of evidence for human RNA-tumor
viruses also exist.
INTRODUCTION
The resurgence of interest in the role of immunologic factors in maligant dis-
ease has been accompanied by marked interest in antigenicity of malignant cells
and, where appropriate, accompanying detailed antigenic analyses of the viruses
responsible for their induction (Geering, et al., 1968; Nowinski, et al., 1972; Schafer,
et al., 1971). These studies have identified new (neo) antigens in or on tumor
cells (Klein, 1966) and in some cases have differentiated between translation from
viral genome or from host-cell genome derepressed by virus infection (Baluda,
1972; Gilden and Oroszlan, 1972; Temin, 1972a; Todaro and Huebner, 1972).
In the case of neoplasms induced by RNA tumor viruses, there is substantial
evidence that a negative strand DNA copy of the RNA-virus genome is made in
the infected cell (Baluda, 1972; Temin, 1972a). This copy serves as template
for synthesis of positive RNA and DNA strands. The DNA copies appear to be
integrated and function as host cell genes. In certain cases it has been demon-
strated that the entire viral genetic code is integrated, but only portions of it are
expressed (Gilden and Oroszlan, 1972). These expressions are identified by the
presence of viral or viral-induced neoantigens in the cell and are often accompanied
by morphologic changes in the cell (transformation).
Apparent partial expression, or conceivably total expression of incomplete
viral genome without transformation—e.g. in chicken (Allen and Sarma, 1972)
and in mouse and cat embryos (Huebner, et al., 1971)—has contributed to the
concept that RNA-tumor viruses are transmitted vertically in a genetic manner
(Huebner and Todaro, 1969; Todaro and Huebner, 1972). The genes so trans-
mitted have been called virogenes. The hypothesis also states that the genetic
information responsible for oncogenesis, called the oncogene, is transmitted sim-
ilarly in close association with the virogenes. (For an alternative and equally
plausible theory see Temin, 1972a, b). The full expression of all virogenes and
oncogenes results in a virus-producing malignant cell. In the adult mouse, the
time (age) and degree of expression of each gene appears to be dependent on host
genetic controls and the influence of other intrinsic and extrinsic factors (Huebner
and Todaro, 1969).
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Although the oncogene-virogene hypothesis is feasible, and is supported by
much evidence from studies in chickens and mice, its acceptance as the only mode
of transmission of RNA tumor viruses is unwarranted. There has been no evidence
presented that the viruses are present in germ cells following meiosis (Todaro and
Huebner, 1972). Horizontal transmission of feline RNA tumor viruses, with both
experimental and naturally occurring virus strains, has been documented (Essex,
et al., 1971a, b; Gardner, et al., 1970; Hardy and Hirshaut, 1971; Rickard, et al.,
1969).
Spontaneous neoplasms have not been reported in germfree cats. Further-
more, in a colony of several hundred cats housed for eight years in a closed environ-
ment wherein natural feline pathogens have been excluded, we have yet to observe
a single neoplasm. This may be highly significant since leukemia and lympho-
sarcoma are major diseases in cats (Hardy and Hirshaut, 1971; Schneider, 1971).
A peak incidence of lymphoma occurs in conventional cats between the first and
second year of life, and the potential lifetime incidence of neoplasms in cats has
been estimated from registry data to be five to ten percent (Schneider, 1971).
In germfree rats, spontaneous tumors arise but are rarely mailigant, and no RNA-
tumor virus has been associated with them (Pollard, 1971).
Another argument originally submitted in support of the virogene-oncogene
hypothesis is that chickens, mice, and cats appeared to be immunologically unre-
sponsive to viral antigens expressed during fetal life (Huebner, et al., 1971), par-
ticularly those viral internal antigens known as group-specific (gs) antigens.
However, evidence has been reported from four different laboratories (Armstrong,
1969; Rabotti and Blackham, 1970; Roth, et al., 1971; Weber and Yohn, 1972)
that chickens are not immunotolerant to avian gs antigens, and two laboratories,
including ours, have described antibodies in cats to feline gs antigens (Noronha,
et al., 1972; Yohn and Olsen, 1972).
At this point it would seem appropriate to define briefly the antigens of RNA
tumor viruses. Simply stated, these viruses consist of an outer envelope derived
from modified host cell-membranes, usually the cytoplasmic membrane, and an
inner nucleoid of proteins and RNA. The outer membrane contains at least two
specific viral glycoproteins of molecular weights of approximately 100,000 and
70,000 (Nowinski, et al., 1972; Oroszlan, et al., 1971). These glycoproteins con-
tain type-specific antigens, but also may contain species-specific and possibly
interspecies antigenic determinates (Schafer, 1972). The core proteins, usually
three or four in mammalian RNA tumor viruses, contain mainly species-group-
specific (gs) antigens. One of these, gs-3 is shared by all C-type mammalian
RNA tumor viruses (Geering, et al., 1968) and is known as an "interspec" antigen
(Schafer, et al., 1971). This latter antigen is also present in two human candi-
date RNA viruses, ESP-1 (Priori, et al., 1971) and RD-114 (McAllister, et al.,
1972). It should be mentioned that the major gs protein of RD-114, gs-1, is
not antigenically related to murine and feline gs-1 antigens (McAllister, et al.,
1972; Nelson-Rees, et al., 1972). It has been suggested that the reported rela-
tionship between ESP-1 virus and murine viruses (Gilden, et al., 1971) may be
associated with a viral protein other than gs-3 that may have interspecies antigenic
determinants (Schafer, 1972).
If ESP-1 and/or RD-114 are truly human RNA tumor viruses, one question
of considerable importance is whether specific antibodies to these viruses are present
in human sera. To answer this question unambiguously would require highly
specific antibodies to the human RNA tumor virus gs and membrane antigens.
Lacking such reagents, a more preliminary question may be asked, namely, do
human sera contain antibodies reactive with the mammalian RNA tumor virus
"interspec" antigen. This question is answerable because mammals are not
immunotolerant to the antigen (Yohn and Olsen, 1972) and produce antibodies
that can be used as reference reagents (Geering, et al., 1968).
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To answer this important question we selected three serologic procedures,
direct micro-CF tests and two tests which do not depend on direct binding of
complement, namely, complement-fixation inhibition (CFI) and inhibition of the
paired radioiodine-labeled antibody technique (PRILAT inhibition). The latter
two procedures have been used to demonstrate the presence of gs antibodies in
chickens (Weber and Yohn, 1972; Yohn, et al., 1971) and in cats (Olsen and Yohn,
1972; Yohn and Olsen, 1972). Briefly, the CFI test (Rice, 1948) involves incu-
bation of dilutions of a human serum with two units of ether-disrupted murine
leukemia virus (MuLV) gs antigen, followed by the addition of two units of
reference antibody and three units of guinea-pig complement (C'50). In the
presence of binding of interspec antigen by the human serum, free complement is
available to lyse sensitized indicator sheep red-blood-cells. In the absence of
competitive binding, the reference antibody reacts with the test antigen and
fixes all the complement. The reference antibody employed in this system was
rabbit anti-FeLV (Ricl. ard strain) and is known to contain antibodies to "inter-
spec" antigens. The antigen was ether-disrupted Rauscher MuLV.
The PRILAT inhibition test has been described in detail by us (Evans and
Yohn, 1970). Briefly, fixed cells known to contain murine gs antigens were in-
cubated with human sera. Appropriate control cells, known to be free of gs
antigens, were similarly incubated. Control cells were human embryonic-kidney
(HEK) while Rauscher-MuLV-infected HEK (HEK-HRV) cells served as test
cells. After appropriate rinsing of the cells, the direct PRILAT test was per-
formed. The antibody in the test was 125I-labeled goat Igg to FeLV mixed with
an equal concentration of 131I-labeled normal goat Igg. The antiserum contained
antibodies to "interspec" antigen and had been absorbed with fetal calf serum
proteins and feline tissue antigens. Inhibition of the PRILAT was accepted as
significant when the proportional uptake of the 125I-labeled antibody on antigen-
containing cells was two standard errors less than the uptake on cells which had
not been incubated with the human serum.
The PRILAT inhibition and CF inhibition tests with murine RNA-tumor-
virus antigen and FeLV reference antibody were designed to test for antibodies in
human sera to "interspec" antigen, since, as far as could be determined, this
antigen-antibody reaction was the only one occurring between these reagents.
Tests of approximately 250 human sera, representing point bleeds from pa-
tients with various malignancies or leukemia and from normal individuals and
family members of patients, were performed. Direct CF tests (using guinea-pig
complement) between the human sera and the MuLV gs antigens were performed
in conjunction with the CFI tests as controls for the latter test. In general, any
sera reactive in direct CF did not react in CFI; only 6 exceptions were noted. The
direct CF results (Table 1) indicated a significant (P<.05) number of positive
reactions among patients with acute lymphocytic leukemia, breast carcinoma, and
metastatic breast carcinoma, and also among normal family members of cancer
patients when compared with the results of tests made on other normal individuals.
However, because of the several different antigens in the virus material, the
reactions can not be interpreted as indicative of antibody to the same antigen in
all sera.
The CFI results (Table 2), however can be interpreted as indicative of anti-
body to "interspec" antigen. In these tests, 40% or more of sera from the ma-jority of disease categories examined were reactive. The only disease categories
with a non-significant number of reactive sera were Hodgkin's disease, 8/32, and
acute leukemia (non-lymphocytic), 1/11. Among normal individuals (non-
family), 9/70 sera (13%) were reactive, while 12/63 (19%) sera from normal
family members of cancer patients were reactive.
One hundred and five sera were tested by PRILAT inhibition (Table 3); of
these, 83 were also tested by CF and CFI (Table 4). The correspondence was
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TABLE 1
Direct CF tests between human sera and Rauscher MuL V (HEK-HR V) gs
antigens using guinea pig complement
Disease Category
None (Normal)
None (Family members)
Sarcoma
Rhabdomyo
Osteogenic
Reticulum cell
Hodgkin's
Lympho
Lipo
Leukemia
Acute lymphocytic
Acute (other)
Chronic lymphocytic
Carcinoma
Adenocarcinoma
Metastatic
62
37
8
8
10
25
16
5
11
8
3
7
4
2
CF Titers
10
22
2
0
1
6
2
1
6
2
0
6
0
3
i—
i
1
0
0
0
1—
1
1
0
0
0
0
0
0
1
— Positive/total
11/73
23/60
2/10
0/8
1/11
7/32
3/19
1/6
6/17
2/10
0/3
6/13
0/4
4/6
P by (x2)
<.O5
ns
ns
ns
ns
ns
ns
<.O5
ns
ns
<.O2
ns
<.O2
essentially 70%, that is, 70% of the sera positive by PRILAT inhibition were also
positive by CF or CFI, and 68% of the sera negative by CF and CFI were negative
by PRILAT inhibition. The criterion that the specific uptake quotient (S.U.Q.)
in the PRILAT inhibition test must be reduced by 2 standard errors may have
resulted in the designation of many sera as falsely negative. By reducing the
inhibition level to 1 standard error, essentially 60% of the PRILAT inhibition
TABLE 2
Complement-fixation inhibition tests for antibody in human sera to "inter spec" antigen
using rabbit anti-FeLV and Rauscher MuLV (HEK-HRV) gs antigens as reference
reagents
Disease Category
None (Normal)
None (family members)
Sarcoma
Rhabdomyo
Osteogenic
Reticulum cell
Hodgkin's
Lympho
Lipo
Leukemia
Acute Lymphocytic
Acute (other)
Chronic Lymphocytic
Breast
CarcinomaAdenocarcinoma
Metastatic
<1:2
61
51
5
0
3
24
5
1
11
10
1
9
0
3
CFI Titers
1:2 to 1:8
7
5
1
1
1
2
3
0
3
1
0
3
0
1
^1:16
2
7
4
6
6
6
7
5
4
0
2
4
4
3
Positive/
Total
9/70
12/63
5/10
7/7
7/10
8/32
10/15
5/6
7/18
1/11
2/3
7/16
4/4
4/7
P by (x2)
ns
<.O5
< .01
<.O5
ns
<.O5
< .01
<.O5
ns
<.10
<.O5
<.O5
<.O5
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TABLE 3
PRILAT-inhibition tests for antibody in human sera to "interspec1'
antigen using goat anti-FeLV and Rauscher MuLV infected
HER cells (HER-HR V)
Disease Category
None (Family Members)
Sarcoma
Rhabdomyo
Osteogenic
Reticulum cell
Hodgkin's
Lympho
Leiomyo
Leukemia
Acute Lymphocytic
Acute (other)
Chronic Lymphocytic
Breast
Carcinoma
Adenocarcinoma
Metastatic
All other tumors
PRILAT-Inhibition
Number Positive/
Number Tested
2/15
3/3
2/3
1/4
4/13
1/7
1/2
1/5
1/7
0/2
1/11
0/1
3/7
6/25
• P b y (x2)
<.O5
<.10
ns
<.10
ns
ns
ns
ns
ns
ns
ns
<.O5
ns
ns = not significant.
negative sera would have been called positive. Future studies will include an-
alyses of the validity of employing reduction of the S.U.Q. by 1 standard error
rather than by 2. The truly discordant sera included 10/83 (12%), which were
PRILAT positive, but negative by CF and CFI; these differences are not
understood.
In spite of the probable high level of false negatives in the PRILAT inhibition
tests, four disease categories were identified that contained a noteworthy propor-
tion of reactive sera. This included patients with rhabdomyosarcoma, (3/3),
osteogenic sarcoma, (2/3), Hodgkin's disease, (4/13), and metastic breast car-
cinoma (3/7). These four diseases and acute lymphocytic leukemia (Table 5)
are considered worthy of further study for antibodies to interspec antigen.
TABLE 4
Correlations between PRILA T inhibition, CF and CFI tests
Ratio Percent
Negative by all 3 tests 21/83 25
Positive by PRILAT and by CF or CFI 24/83 29
Negative by PRILAT and positive by
CF or CFI 28/83 34
Positive by PRILAT and negative by
CF and CFI 10/83 12
Percent of PRILAT positive sera that
were CF or CFI positive 70
Percent of CF and CFI negative sera
that wer PRILAT negative 68
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TABLE 5
Composite results of CF, CFI and PRILA T tests in selected diseases for
antibodies to "interspec" antigen
Disease Category
None (Family Members)
Rhabdomyosarcoma
Osteogenic Sarcoma
Hodgkin's Disease
Acute Lymphocytic Leukemia
Breast Cancer
*P=<.05 by X2.
Number
CF
23/60
2/10
0/8
7/32
6/17*
10/23*
Positive/Number Tested
CFI
12/63
5/10*
7/7*
8/32
7/18*
15/27*
PRILAT
2/15
3/3*
2/3
4/13
1/5
4/19
The evidence presented is indicative that many patients with the diseases
listed in Table 5 have responded immunologically to the mammalian interspec
RNA-tumor virus antigen. Does this mean that their disease has been induced
by an RNA-tumor virus? At this point one can not answer the question. How-
ever, if one evaluates the data in Table 5 in the light of other already-existing
evidence that human RNA-tumor viruses exist, one can not overlook the pos-
sibility that RNA-tumor viruses are involved in the etiology of human cancer
and leukemia.
The evidence to date includes:
1) observations, by electron microscopy, of RNA-tumor-virus particles in human
clinical material (Dmochowski, 1971; Hall, et al, 1970; Seman, et al, 1969;
Seman, et al, 1971; Shigematsu, et al., 1971; Schlom, et al., 1971);
2) isolation of infectious RNA-tumor viruses from cell cultures of human origin
(Priori, et al., 1971; McAllister, et al., 1972; Stewart, et al., 1972);
3) presence of RNA in human tumors which hybridizes with appropriate copies
of nucleic acid from RNA-tumor virus (Kufe, et al., 1972; Schlom, et al.,
1972);
4) presence of viral-like RNA-dependent DNA polymerase in human clinical
material (Gallo, et al., 1970; Gallo, et al., 1971, and Gallo, et al, 1972;
Kiessling, et al., 1971; Schlom, et al., 1971);
5) antigens in human cancer cells which appear to be disease specific (Eilber and
Morton, 1970; Giraldo, et al, 1971; morton and Malgren, 1968);
6) antibodies in human sera which appear to be disease specific (Eilber and
Morton, 1970; Morton and Malmgren, 1968); and finally,
7) the evidence given herein that in human sera antibodies are present that
react with mammalian RNA-tumor virus interspec antigen.
Perhaps the most hopeful conclusion one can make from the present studies
is that humans appear to be immunoresponsive to RNA-tumor-virus antigens.
This may mean that early immunodiagnostic tests and control by immunologic
procedures are feasible.
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